Medications for Severe Asthma

4 results

  • cinqair

    (Reslizumab)
    Teva Respiratory, LLC
    CINQAIR® is indicated as an add-on maintenance treatment for adults (18+) with severe asthma exhibiting an eosinophilic phenotype. It is not intended for other eosinophilic conditions or for acute bronchospasm relief or status asthmaticus.

  • fasenra

    (Benralizumab)
    AstraZeneca Pharmaceuticals LP
    FASENRA is indicated for the add-on maintenance treatment of severe asthma in patients aged 6 years and older with an eosinophilic phenotype and for treating eosinophilic granulomatosis with polyangiitis (EGPA) in adults. It is not for acute bronchospasm relief.

  • nucala

    (mepolizumab)
    GlaxoSmithKline LLC
    NUCALA is indicated for the add-on maintenance treatment of severe asthma (ages 6+), chronic rhinosinusitis with nasal polyps (ages 18+), inadequate chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis in adults, and hypereosinophilic syndrome in patients aged 12 and older.

  • tezspire

    (tezepelumab-ekko)
    Amgen, Inc
    TEZSPIRE is indicated as an add-on maintenance treatment for severe asthma in patients aged 12 years and older. It is not meant for immediate relief of acute bronchospasm or status asthmaticus.